baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Alnylam Pharmaceuticals/ US02043Q1076 /

2024-04-18 9:59:55 PM	Chg. -0.19	Volume	Bid-	Ask-	High	Low
145.05USD	-0.13%	19,232 Turnover: 2.8 mill.	-Bid Size: -	-Ask Size: -	146.47	144.51

GlobeNewswire 04-11 Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

GlobeNewswire 04-01 Autolus Therapeutics Announces Changes to its Board of Directors

GlobeNewswire 03-15 American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...

GlobeNewswire 03-13 3Daughters Announces Three New Appointments to Board of Directors

GlobeNewswire 03-07 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmace...

GlobeNewswire 03-06 Zenas BioPharma Appoints Patricia Allen to its Board of Directors

GlobeNewswire 02-29 Kidney Month: 31 Day of Action to Equip and Empower People to Fight Kidney Disease

GlobeNewswire 02-28 Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

GlobeNewswire 02-28 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmace...

GlobeNewswire 02-20 Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

GlobeNewswire 02-02 Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

GlobeNewswire 01-17 Mary Beth DeLena Joins PepGen as General Counsel and Secretary

GlobeNewswire 2023-12-13 Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

GlobeNewswire 2023-12-11 Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeuti...

GlobeNewswire 2023-11-28 Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics...

GlobeNewswire 2023-11-28 Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

GlobeNewswire 2023-11-14 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmace...

GlobeNewswire 2023-11-09 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible S...

GlobeNewswire 2023-11-08 SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an I...

GlobeNewswire 2023-11-07 SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Alnylam Pharmaceuticals, Inc. (ALNY) ...

GlobeNewswire 2023-11-06 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible S...

GlobeNewswire 2023-11-05 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmac...

GlobeNewswire 2023-11-03 Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blo...

GlobeNewswire 2023-11-02 Codexis Reports Third Quarter 2023 Financial Results

GlobeNewswire 2023-11-02 SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an I...

Alnylam Pharmaceuticals/ US02043Q1076 /

If you wish to receive reply to your feedback, please provide your email address.